Inflammation in COPD: Implications for management

American Journal of Medicine

Volumn 125, Issue 12, 2012, Pages 1162-1170

  Sethi, Sanjay ^a   Mahler, Donald A ^b   Marcus, Philip ^c   Owen, Caroline A ^d   Yawn, Barbara ^e   Rennard, Stephen ^f  

^a UNIVERSITY AT BUFFALO   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^c ST FRANCIS HOSPITAL   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e OLMSTED MEDICAL CENTER   (United States)

^f UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Anti inflammatory; COPD; Exacerbation; Inflammation

Indexed keywords

ANTIINFLAMMATORY AGENT; ARFORMOTEROL; BRONCHODILATING AGENT; BUDESONIDE; CHEMOKINE; CORTICOSTEROID; CYTOKINE; FLUTICASONE; FORMOTEROL; INDACATEROL; INFLIXIMAB; INTERLEUKIN 6; INTERLEUKIN 8; MACROLIDE; MUCOLYTIC AGENT; PHOSPHODIESTERASE IV INHIBITOR; PLACEBO; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ROFLUMILAST; SALMETEROL; STATIN; STEROID; THEOPHYLLINE; TIOTROPIUM BROMIDE; TUMOR NECROSIS FACTOR ALPHA;

ASTHMA; B LYMPHOCYTE; CANDIDIASIS; CHRONIC INFLAMMATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; DENDRITIC CELL; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; EOSINOPHIL; HOARSENESS; HUMAN; INFLAMMATORY CELL; LYMPHOCYTE; MACROPHAGE; MAST CELL; NEUTROPHIL; OXIDATIVE STRESS; PATHOGENESIS; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; AIRWAY REMODELING; ANTI-INFLAMMATORY AGENTS; ASTHMA; BRONCHODILATOR AGENTS; CYTOKINES; EOSINOPHILS; GLUCOCORTICOIDS; HUMANS; INFLAMMATION; LYMPHOCYTES; MUSCARINIC ANTAGONISTS; NEUTROPHILS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84869161577     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2012.06.024     Document Type: Review

References (94)

1. World Health Organization (WHO) The global burden of disease: 2004 update http://www.who.int/healthinfo/global-burden-disease/GBD-report-2004update-full. pdf Accessed January 14, 2011
2. C.J. Murray, A.D. Lopez Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study Lancet 349 1997 1498 1504
3. Centers for Disease Control and Prevention, Division of Vital Statistics Deaths: preliminary data for 2008 http://www.cdc.gov/nchs/data/nvsr/nvsr59/ nvsr59-02.pdf Accessed February 16, 2011
4. Global Initiative for Chronic Obstructive Lung Disease (GOLD) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (revised 2011) http://www.goldcopd.org/guidelines-global- strategy-for-diagnosis-management.html Accessed January 31, 2012
5. P.J. Barnes Immunology of asthma and chronic obstructive pulmonary disease Nat Rev Immunol 8 2008 183 192
6. M.L. Levy, M. Fletcher, D.B. Price International Primary Care Respiratory Group (IPCRG) Guidelines: diagnosis of respiratory diseases in primary care Prim Care Respir J 15 2006 20 34
7. D. Bellamy, J. Bouchard, S. Henrichsen International Primary Care Respiratory Group (IPCRG) Guidelines: management of chronic obstructive pulmonary disease (COPD) Prim Care Respir J 15 2006 48 57
8. B.R. Celli, W. MacNee Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper Eur Respir J 23 2004 932 946
9. J.C. Hogg, F. Chu, S. Utokaparch The nature of small-airway obstruction in chronic obstructive pulmonary disease N Engl J Med 350 2004 2645 2653
10. V.M. Keatings, P.D. Collins, D.M. Scott, P.J. Barnes Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma Am J Respir Crit Care Med 153 1996 530 534
11. T.C. O'Shaughnessy, T.W. Ansari, N.C. Barnes, P.K. Jeffery Inflammation in bronchial biopsies of subjects with chronic bronchitis: inverse relationship of CD8+ T lymphocytes with FEV1 Am J Respir Crit Care Med 155 1997 852 857
12. P.J. Barnes Emerging pharmacotherapies for COPD Chest 134 2008 1278 1286
13. J.C. Hogg Pathophysiology of airflow limitation in chronic obstructive pulmonary disease Lancet 364 2004 709 721
14. J.C. Hogg, W. Timens The pathology of chronic obstructive pulmonary disease Annu Rev Pathol 4 2009 435 459
15. P.J. Barnes, S.D. Shapiro, R.A. Pauwels Chronic obstructive pulmonary disease: molecular and cellular mechanisms Eur Respir J 22 2003 672 688
16. R. O'Donnell, D. Breen, S. Wilson, R. Djukanovic Inflammatory cells in the airways in COPD Thorax 61 2006 448 454
17. B.W. Willemse, D.S. Postma, W. Timens, N.H. ten Hacken The impact of smoking cessation on respiratory symptoms, lung function, airway hyperresponsiveness and inflammation Eur Respir J 23 2004 464 476
18. A. Anzueto Impact of exacerbations on COPD Eur Respir Rev 19 2010 113 118
19. J. Rizkallah, S.F. Man, D.D. Sin Prevalence of pulmonary embolism in acute exacerbations of COPD: a systematic review and metaanalysis Chest 135 2009 786 793
20. A. Bhowmik, T.A. Seemungal, R.J. Sapsford, J.A. Wedzicha Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations Thorax 55 2000 114 120
21. E. Bathoorn, H. Kerstjens, D. Postma, W. Timens, W. MacNee Airways inflammation and treatment during acute exacerbations of COPD Int J Chron Obstruct Pulmon Dis 3 2008 217 229
22. E. Bathoorn, J.J. Liesker, D.S. Postma Change in inflammation in out-patient COPD patients from stable phase to a subsequent exacerbation Int J Chron Obstruct Pulmon Dis 4 2009 101 109
23. K. Fujimoto, M. Yasuo, K. Urushibata Airway inflammation during stable and acutely exacerbated chronic obstructive pulmonary disease Eur Respir J 25 2005 640 646
24. P.F. Mercer, J.K. Shute, A. Bhowmik MMP-9, TIMP-1 and inflammatory cells in sputum from COPD patients during exacerbation Respir Res 6 2005 151
25. A. Papi, C.M. Bellettato, F. Braccioni Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations Am J Respir Crit Care Med 173 2006 1114 1121
26. S. Sethi, C. Wrona, K. Eschberger Inflammatory profile of new bacterial strain exacerbations of chronic obstructive pulmonary disease Am J Respir Crit Care Med 177 2008 491 497
27. R. Louis, L.C. Lau, A.O. Bron The relationship between airways inflammation and asthma severity Am J Respir Crit Care Med 161 2000 9 16
28. A.B. Thompson, D. Daughton, R.A. Robbins Intraluminal airway inflammation in chronic bronchitis Characterization and correlation with clinical parameters Am Rev Respir Dis 140 1989 1527 1537
29. C.M. Sköld Remodeling in asthma and COPD - differences and similarities Clin Respir J 4 Suppl 1 2010 20 27
30. G.W. Canonica Treating asthma as an inflammatory disease Chest 130 2006 21S 28S
31. M. Broekema, W. Timens, J.M. Vonk Persisting remodeling and less airway wall eosinophil activation in complete remission of asthma Am J Respir Crit Care Med 183 2011 310 316
32. S.T. Holgate, R. Polosa The mechanisms, diagnosis, and management of severe asthma in adults Lancet 368 2006 780 793
33. R. Chaudhuri, E. Livingston, A.D. McMahon Effects of smoking cessation on lung function and airway inflammation in smokers with asthma Am J Respir Crit Care Med 174 2006 127 133
34. G.W. Chalmers, K.J. MacLeod, L. Thomson Smoking and airway inflammation in patients with mild asthma Chest 120 2001 1917 1922
35. A. Jatakanon, C. Uasuf, W. Maziak Neutrophilic inflammation in severe persistent asthma Am J Respir Crit Care Med 160 1999 1532 1539
36. S.S. Birring, M. Berry, C.E. Brightling, I.D. Pavord Eosinophilic bronchitis: clinical features, management and pathogenesis Am J Respir Med 2 2003 169 173
37. P.A. Wark, P.G. Gibson Asthma exacerbations. 3: Pathogenesis Thorax 61 2006 909 915
38. R.A. Stockley Progression of chronic obstructive pulmonary disease: impact of inflammation, comorbidities and therapeutic intervention Curr Med Res Opin 25 2009 1235 1245
39. T.M. Wilkinson, J.R. Hurst, W.R. Perera Effect of interactions between lower airway bacterial and rhinoviral infection in exacerbations of COPD Chest 129 2006 317 324
40. M. Tumkaya, S. Atis, C. Ozge Relationship between airway colonization, inflammation and exacerbation frequency in COPD Respir Med 101 2007 729 737
41. K.H. Groenewegen, D.S. Postma, W.C. Hop Increased systemic inflammation is a risk factor for COPD exacerbations Chest 133 2008 350 357
42. V. Pinto-Plata, J. Toso, K. Lee Profiling serum biomarkers in patients with COPD: associations with clinical parameters Thorax 62 2007 595 601
43. E. Kupeli, G. Ulubay, S.S. Ulasli Metabolic syndrome is associated with increased risk of acute exacerbation of COPD: a preliminary study Endocrine 38 2010 76 82
44. W.R. Perera, J.R. Hurst, T.M. Wilkinson Inflammatory changes, recovery and recurrence at COPD exacerbation Eur Respir J 29 2007 527 534
45. V.M. Pinto-Plata, G. Livnat, M. Girish Systemic cytokines, clinical and physiological changes in patients hospitalized for exacerbation of COPD Chest 131 2007 37 43
46. G. Rohde, P. Gevaert, G. Holtappels Soluble interleukin-5 receptor alpha is increased in acute exacerbation of chronic obstructive pulmonary disease Int Arch Allergy Immunol 135 2004 54 61
47. S.I. Rennard, C. Fogarty, S. Kelsen The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease Am J Respir Crit Care Med 175 2007 926 934
48. D.P. Tashkin Long-acting anticholinergic use in chronic obstructive pulmonary disease: efficacy and safety Curr Opin Pulm Med 16 2010 97 105
49. D.P. Tashkin, L.M. Fabbri Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents Respir Res 11 2010 149
50. K. Asano, Y. Shikama, Y. Shibuya Suppressive activity of tiotropium bromide on matrix metalloproteinase production from lung fibroblasts in vitro Int J Chron Obstruct Pulmon Dis 3 2008 781 789
51. F. Buhling, N. Lieder, U.C. Kuhlmann, N. Waldburg, T. Welte Tiotropium suppresses acetylcholine-induced release of chemotactic mediators in vitro Respir Med 101 2007 2386 2394
52. D.W. Perng, C.W. Tao, K.C. Su Anti-inflammatory effects of salmeterol/fluticasone, tiotropium/fluticasone or tiotropium in COPD Eur Respir J 33 2009 778 784
53. M.P. Pieper, N.I. Chaudhary, J.E. Park Acetylcholine-induced proliferation of fibroblasts and myofibroblasts in vitro is inhibited by tiotropium bromide Life Sci 80 2007 2270 2273
54. M. Profita, A. Bonanno, L. Siena Acetylcholine mediates the release of IL-8 in human bronchial epithelial cells by a NFkB/ERK-dependent mechanism Eur J Pharmacol 582 2008 145 153
55. L. Wollin, M.P. Pieper Tiotropium bromide exerts anti-inflammatory activity in a cigarette smoke mouse model of COPD Pulm Pharmacol Ther 23 2010 345 354
56. P.B. Bolton, P. Lefevre, D.M. McDonald Salmeterol reduces early- and late-phase plasma leakage and leukocyte adhesion in rat airways Am J Respir Crit Care Med 155 1997 1428 1435
57. L.E. Donnelly, S.J. Tudhope, P.S. Fenwick, P.J. Barnes Effects of formoterol and salmeterol on cytokine release from monocyte-derived macrophages Eur Respir J 36 2010 178 186
58. J. Loven, N. Svitacheva, A. Jerre, A. Miller-Larsson, S.H. Korn Anti-inflammatory activity of beta2-agonists in primary lung epithelial cells is independent of glucocorticoid receptor Eur Respir J 30 2007 848 856
59. E. Mortaz, M.V. Rad, M. Johnson Salmeterol with fluticasone enhances the suppression of IL-8 release and increases the translocation of glucocorticoid receptor by human neutrophils stimulated with cigarette smoke J Mol Med 86 2008 1045 1056
60. L. Ottonello, P. Morone, P. Dapino, F. Dallegri Inhibitory effect of salmeterol on the respiratory burst of adherent human neutrophils Clin Exp Immunol 106 1996 97 102
61. D.W. Reid, C. Ward, N. Wang Possible anti-inflammatory effect of salmeterol against interleukin-8 and neutrophil activation in asthma in vivo Eur Respir J 21 2003 994 999
62. C.L. Skevaki, I. Christodoulou, I.S. Spyridaki Budesonide and formoterol inhibit inflammatory mediator production by bronchial epithelial cells infected with rhinovirus Clin Exp Allergy 39 2009 1700 1710
63. P.J. Barnes Inhaled corticosteroids in COPD: a controversy Respiration 80 2010 89 95
64. P.S. Burge, P.M. Calverley, P.W. Jones Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial BMJ 320 2000 1297 1303
65. M.B. Drummond, E.C. Dasenbrook, M.W. Pitz, D.J. Murphy, E. Fan Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis JAMA 300 2008 2407 2416
66. R.A. Pauwels, C.G. Lofdahl, L.A. Laitinen Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking European Respiratory Society Study on Chronic Obstructive Pulmonary Disease N Engl J Med 340 1999 1948 1953
67. I.A. Yang, K.M. Fong, E.H. Sim, P.N. Black, T.J. Lasserson Inhaled corticosteroids for stable chronic obstructive pulmonary disease Cochrane Database Syst Rev 2 2007 CD002991
68. B.R. Celli, N.E. Thomas, J.A. Anderson Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study Am J Respir Crit Care Med 178 2008 332 338
69. J.B. Soriano, D.D. Sin, X. Zhang A pooled analysis of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placebo Chest 131 2007 682 689
70. E.R. Sutherland, H. Allmers, N.T. Ayas, A.J. Venn, R.J. Martin Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis Thorax 58 2003 937 941
71. T.S. Lapperre, J.B. Snoeck-Stroband, M.M. Gosman Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial Ann Intern Med 151 2009 517 527
72. K.L. Hattotuwa, M.J. Gizycki, T.W. Ansari, P.K. Jeffery, N.C. Barnes The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study Am J Respir Crit Care Med 165 2002 1592 1596
73. I.M. Adcock, J. Marwick, P. Casolari Mechanisms of corticosteroid resistance in severe asthma and chronic obstructive pulmonary disease (COPD) Curr Pharm Des 16 2010 3554 3573
74. K. Ito, M. Ito, W.M. Elliott Decreased histone deacetylase activity in chronic obstructive pulmonary disease N Engl J Med 352 2005 1967 1976
75. J. Bourbeau, P. Christodoulopoulos, F. Maltais Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial Thorax 62 2007 938 943
76. S.V. Culpitt, W. Maziak, S. Loukidis Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease Am J Respir Crit Care Med 160 1999 1635 1639
77. S.V. Culpitt, D.F. Rogers, P. Shah Impaired inhibition by dexamethasone of cytokine release by alveolar macrophages from patients with chronic obstructive pulmonary disease Am J Respir Crit Care Med 167 2003 24 31
78. V.M. Keatings, A. Jatakanon, Y.M. Worsdell, P.J. Barnes Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD Am J Respir Crit Care Med 155 1997 542 548
79. B.G. Cosio, A. Iglesias, A. Rios Low-dose theophylline enhances the anti-inflammatory effects of steroids during exacerbations of COPD Thorax 64 2009 424 429
80. P.A. Ford, A.L. Durham, R.E. Russell Treatment effects of low-dose theophylline combined with an inhaled corticosteroid in COPD Chest 137 2010 1338 1344
81. E.D. Bateman, S.S. Hurd, P.J. Barnes Global strategy for asthma management and prevention: GINA executive summary Eur Respir J 31 2008 143 178
82. C.M. Skold Remodeling in asthma and COPD - differences and similarities Clin Respir J 4 Suppl 1 2010 20 27
83. K.F. Rabe, S. Hurd, A. Anzueto Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary Am J Respir Crit Care Med 176 2007 532 555
84. P.M. Calverley, J.A. Anderson, B. Celli Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease N Engl J Med 356 2007 775 789
85. N.C. Barnes, Y.S. Qiu, I.D. Pavord Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease Am J Respir Crit Care Med 173 2006 736 743
86. P.A. Martorana, R. Beume, M. Lucattelli, L. Wollin, G. Lungarella Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smoke Am J Respir Crit Care Med 172 2005 848 853
87. L.M. Fabbri, P.M. Calverley, J.L. Izquierdo-Alonso Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials Lancet 374 2009 695 703
88. D.A. Mahler, S. Huang, M. Tabrizi, G.M. Bell Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: a pilot study Chest 126 2004 926 934
89. M.G. Matera, L. Calzetta, M. Cazzola TNF-alpha inhibitors in asthma and COPD: we must not throw the baby out with the bath water Pulm Pharmacol Ther 23 2010 121 128
90. S. Suissa, P. Ernst, M. Hudson TNF-alpha antagonists and the prevention of hospitalisation for chronic obstructive pulmonary disease Pulm Pharmacol Ther 21 2008 234 238
91. R.G. Barr, B.R. Celli, F.J. Martinez Physician and patient perceptions in COPD: the COPD Resource Network Needs Assessment Survey Am J Med 118 2005 1415
92. B.P. Yawn, P.C. Wollan Knowledge and attitudes of family physicians coming to COPD continuing medical education Int J Chron Obstruct Pulmon Dis 3 2008 311 317
93. J.A. Foster, B.P. Yawn, A. Maziar, T. Jenkins, S.I. Rennard, L. Casebeer Enhancing COPD management in primary care settings MedGenMed 9 2007 24
94. P.J. Barnes New therapies for chronic obstructive pulmonary disease Med Princ Pract 19 2010 330 338